Prof. Melo             Prof. Hughes     A/Prof. Branford

Session 1: Front line Therapy of CML-CP

• Addressing key biological questions in CML 
  (Prof. Junia Melo)
• Risk profiles, molecular targets, pharmacokinetics 
  (Prof. Timothy Hughes)
• The importance of deep molecular response in CML patients 
  (A/Prof. Susan Branford) 

Addressing the Key Biological Questions in CML

Prof. Junia Melo - University of Adelaide

• Pitfalls of tyrosine kinase inhibitor therapy
• The role of B-lymphoid kinase (Blk) in CML development
• Regulation of Blk and the role of Pax5 and cyclin-dependent kinase inhibitor p27
• Critical molecular pathways in LSCs
• Other key biological questions

Risk Profiles, Molecular Targets and Pharmacokinetics
Prof. Timothy Hughes - SA Pathology, University of Adelaide

• Ways to optimize CML Therapy:
  • Towards an accurate risk profile
  • Early molecular response
  • Kinase inibition/pharmacokinetics
• Study results from the ENESTxtnd sub-study of Australian patients
  and the OPTIM Dasatinib trial

The Importance of Deep Molecular Response for Patients with CML
A/Prof. Susan Branford - Centre for Cancer & Biology, Universities of Adelaide and South Australia

• Importance of deep molecular reponse in CML
• Time duration to achieve deep molecular response
• Factors associated with deep molecuar response
• Discontinuation trial criteria
• Patient cases and clinical studies with patients on imatinib based therapy